Windtree Therapeutics (NSDQ:WINT) today released data from a phase IIa trial evaluating its inhaled Aerosurf lucinactant designed for premature infants with respiratory distress syndrome.
Results from the trial were presented at the 6th International Congress of European Neonatal and Perinatal Societies in Valencia, Spain.
Premature babies often lack adequate surfactant – a naturally occurring substance that reduces the surface tension of fluids in the lungs and helps to enable stable breathing. To make up for an insufficient supply of surfactant, doctors use lucinactant replacement therapy in a liquid formulation immediately after birth in order to help the child breathe.
Get the full story at our sister site, Drug Delivery Business News.
The post Windtree touts inhaled therapy for infants with respiratory distress syndrome appeared first on MassDevice.
from MassDevice http://ift.tt/2fNEY6S
Cap comentari:
Publica un comentari a l'entrada